Allergan makes case for Botox as migraine treatment
This article was originally published in Scrip
Executive Summary
Allergan has presented pooled analysis of the mixed Phase III data that was used to support the US filing it made last year for Botox (onabotulinumtoxinA), a treatment of chronic migraines, a market that may affect as many as 2.4% of the US population. An FDA decision is expected later this year.